Accumulating evidence revealed that degradation of oncoproteins may contribute to countering the almost inevitable drug resistance due to target inhibition, and increase the peptide presentation capability of MHC molecules which synergize with cancer immunotherapy [5, 7], implying that targeting E3s may provide a promising access for therapeutic intervention of cancer. The gene discussed is HLA-C; the disease is cancer.